Acadia Pharmaceuticals (ACAD) Cash from Operations (2010 - 2026)

Acadia Pharmaceuticals' Cash from Operations history runs 17 years deep, the most recent figure standing at 33981000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 67.2% year-over-year to 33981000.0; the TTM figure through Mar 2026 stood at 123494000.0 (down 17.1% YoY), while the FY2025 annual figure was 109836000.0, down 30.36% from the prior year.
• Cash from Operations was 33981000.0 for Q1 2026 at Acadia Pharmaceuticals, up from 48731000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 85389000.0 in Q4 2023 to a low of 76329000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 12011941.18 across 5 years, with a median of 20323000.0 in 2025.
• Biggest YoY gain for Cash from Operations was 457.97% in 2023; the steepest drop was 8009.35% in 2023.
• A 5-year view of Cash from Operations shows it stood at 23854000.0 in 2022, then soared by 457.97% to 85389000.0 in 2023, then tumbled by 52.71% to 40381000.0 in 2024, then sank by 220.68% to 48731000.0 in 2025, then soared by 169.73% to 33981000.0 in 2026.
• The last three Cash from Operations figures came in at 33981000.0 (Q1 2026), 48731000.0 (Q4 2025), and 74288000.0 (Q3 2025), per Business Quant data.